These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. [Diagnostic value of SATB2, CK7 and CK20 in colorectal cancer]. Lyn J, Wang Y, Wang F, Shen M, Zhou X. Zhonghua Bing Li Xue Za Zhi; 2015 Aug; 44(8):578-81. PubMed ID: 26705182 [Abstract] [Full Text] [Related]
44. Identifying colorectal metastases in liver biopsies: the novel CDX2 antibody is less specific than the cytokeratin 20+/7- phenotype. Tot T. Med Sci Monit; 2004 May; 10(5):BR139-43. PubMed ID: 15114262 [Abstract] [Full Text] [Related]
45. Utility of thyroid transcription factor-1 and cytokeratin 7 and 20 immunostaining in the identification of origin in malignant effusions. Jang KY, Kang MJ, Lee DG, Chung MJ. Anal Quant Cytol Histol; 2001 Dec; 23(6):400-4. PubMed ID: 11777274 [Abstract] [Full Text] [Related]
46. Serrated pathway adenocarcinomas: molecular and immunohistochemical insights into their recognition. Gurzu S, Szentirmay Z, Toth E, Bara T, Bara T, Jung I. PLoS One; 2013 Dec; 8(3):e57699. PubMed ID: 23469219 [Abstract] [Full Text] [Related]
48. Coexpression of cytokeratins 7 and 20 confirms urothelial carcinoma presenting as an intrarenal tumor. Han AC, Duszak R. Cancer; 1999 Dec 01; 86(11):2327-30. PubMed ID: 10590374 [Abstract] [Full Text] [Related]
49. The use of cytokeratins 7 and 20 in the diagnosis of primary and secondary extramammary Paget's disease. Ohnishi T, Watanabe S. Br J Dermatol; 2000 Feb 01; 142(2):243-7. PubMed ID: 10730755 [Abstract] [Full Text] [Related]
50. Aberrant pattern of the cytokeratin 7/cytokeratin 20 immunophenotype in colorectal adenocarcinomas with BRAF mutations. Gurzu S, Jung I. Pathol Res Pract; 2012 Mar 15; 208(3):163-6. PubMed ID: 22361037 [Abstract] [Full Text] [Related]
51. Expression of cytokeratins 7 and 20 in carcinomas of the gastrointestinal tract. Kende AI, Carr NJ, Sobin LH. Histopathology; 2003 Feb 15; 42(2):137-40. PubMed ID: 12558745 [Abstract] [Full Text] [Related]
53. [Expression of cytokeratin 7 and 20 in ovarian metastatic carcinomas]. Dai L, Song Q, Li L, Zhong D, Hui Y. Zhonghua Bing Li Xue Za Zhi; 2001 Apr 15; 30(2):114-7. PubMed ID: 11866966 [Abstract] [Full Text] [Related]
54. Differential expression of CK7, CK20, CDX2 in intestinal and pancreatobiliary types of preriampullary carcinoma. Sree UD, Prayaga AK, R Reddy VV, Rukmanghadha N, Chowhan AK, Phaneendra BV. Indian J Pathol Microbiol; 2022 Apr 15; 65(1):42-48. PubMed ID: 35074964 [Abstract] [Full Text] [Related]
55. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology. Alsheikh A, Mohamedali Z, Jones E, Masterson J, Gilks CB. Mod Pathol; 2001 Apr 15; 14(4):267-72. PubMed ID: 11301341 [Abstract] [Full Text] [Related]
59. Clinicopathological and immunohistochemical study of 20 choroid plexus tumors: their histological diversity and the expression of markers useful for differentiation from metastatic cancer. Ikota H, Tanaka Y, Yokoo H, Nakazato Y. Brain Tumor Pathol; 2011 Jul 15; 28(3):215-21. PubMed ID: 21394517 [Abstract] [Full Text] [Related]